A good start to the New Year last week with the FTSE 100 rising almost 200 points to close the week at 6,090 points. The AIM All Share also followed the trend with a rise from 707 points to 719 points. News included a short term deal being signed on the US fiscal cliff which helped the markets to rally, whilst retail sales in the UK in December were up 1.5 per cent compared to the prior December and UK manufacturing was also said to have risen to a 15 month high in December with a PMI of 51.4 versus 49.2 the month before. The week ahead sees the Bank of England MPC announcement, UK trade figures, UK monthly manufacturing output and industrial production figures being announced.
Disclaimer- This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only- please refer to the disclaimer in full below.
ANCR supply of product resumes, ATC Loan Extension, BSE Admission to AIM, BLUR New appointments, CGNR Metallurgical Test Work Positive, CYAN Partner deployment, DDD Expansion of Yabazam, ESG Preliminary results, GTC New contracts worth $2m, MAGP Quarterly update, MDZ interims and placing, MIRA Contract win, NPT Trading Update, MOU with Botswanan Company, PINN Board Changes, PREM granted two permits, RXP $40m equity investment, SNCL Audited Preliminary Results, SORB agreement with APAC and update on Loan Notes, TYR New Anti-Endoparasitic Composition Patents, SQS Largest Contract Win & Contract, VIY Chevron Expands Contract
Animalcare (LON:ANCR) Group (LON:ANCR 145p/£30.04m)
A leading supplier of veterinary medicines last week announced that the sale of Buprecare single dose ampoules has resumed following the break in supply announced in July 2011. A new contract has been signed with a German multinational contract manufacturer with a substantial sterile injectables facility in France and that facility has now been approved to manufacture Buprecare single dose ampoules. Buprecare single dose ampoules from the new supplier are now available for sale in all previously supplied markets in the UK and Europe. Animalcare management is confident about the new supply of Buprecare ampoules and is also confident that levels of sales similar to those prior to the supply disruption will be reached. Buprecare multi dose vial, an analgesic for cats and dogs launched in March 2012, continues to sell well. Its strong performance is expected to complement the sale…
